- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 10 - Treating Mild and Severe Hemophilia
During this segment, Patrick F. Fogarty, MD, discusses the treatment goals for hemophilia, based on disease severity.
Dr Fogarty defines prophylaxis, explains primary and secondary prophylaxis for the treatment of mild and severe hemophilia, and discusses the recommended target trough levels and dosage requirements based on disease severity.
He continues by discussing how treatment expectations are similar between patients, their family members, and providers. From a pediatric standpoint, Dr Fogarty stresses the importance of providing patients the best opportunity for a normal lifestyle, and explains that as longer-acting proteins continue to develop, there is an opportunity to administer intravenous therapy less frequently.
Dr Fogarty concludes by briefly discussing the benefits of the agents that are currently available to treat patients with mild and severe hemophilia, and cites a recent study that treated patients with a regimen of recombinant clotting factor 8 concentrate and revealed positive results on patients’ quality of life.
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
